JP2010500360A5 - - Google Patents

Download PDF

Info

Publication number
JP2010500360A5
JP2010500360A5 JP2009523863A JP2009523863A JP2010500360A5 JP 2010500360 A5 JP2010500360 A5 JP 2010500360A5 JP 2009523863 A JP2009523863 A JP 2009523863A JP 2009523863 A JP2009523863 A JP 2009523863A JP 2010500360 A5 JP2010500360 A5 JP 2010500360A5
Authority
JP
Japan
Prior art keywords
soluble
tnf
receptor
use according
receptor protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009523863A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010500360A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/017800 external-priority patent/WO2008021237A1/en
Publication of JP2010500360A publication Critical patent/JP2010500360A/ja
Publication of JP2010500360A5 publication Critical patent/JP2010500360A5/ja
Pending legal-status Critical Current

Links

JP2009523863A 2006-08-10 2007-08-10 炎症性サイトカイン阻害剤による下気道炎症疾患の局所療法 Pending JP2010500360A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83676006P 2006-08-10 2006-08-10
US87838507P 2007-01-04 2007-01-04
US90702807P 2007-03-16 2007-03-16
PCT/US2007/017800 WO2008021237A1 (en) 2006-08-10 2007-08-10 Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors

Publications (2)

Publication Number Publication Date
JP2010500360A JP2010500360A (ja) 2010-01-07
JP2010500360A5 true JP2010500360A5 (enExample) 2010-09-24

Family

ID=39082316

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009523863A Pending JP2010500360A (ja) 2006-08-10 2007-08-10 炎症性サイトカイン阻害剤による下気道炎症疾患の局所療法

Country Status (14)

Country Link
US (5) US8940683B2 (enExample)
EP (2) EP2068889B1 (enExample)
JP (1) JP2010500360A (enExample)
AU (1) AU2007284690A1 (enExample)
CA (2) CA2660519A1 (enExample)
CY (1) CY1122533T1 (enExample)
DK (1) DK2068889T3 (enExample)
ES (1) ES2766770T3 (enExample)
HU (1) HUE048024T2 (enExample)
LT (1) LT2068889T (enExample)
PL (1) PL2068889T3 (enExample)
PT (1) PT2068889T (enExample)
SI (1) SI2068889T1 (enExample)
WO (1) WO2008021237A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US9895444B2 (en) * 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
CA2660519A1 (en) 2006-08-10 2008-02-21 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
EA200901494A1 (ru) 2007-06-06 2010-06-30 Домантис Лимитед Способы селекции протеазоустойчивых полипептидов
WO2009049159A1 (en) 2007-10-10 2009-04-16 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
PL2259774T3 (pl) 2008-02-27 2013-04-30 Biomet Biologics Llc Sposoby i kompozycje dla wprowadzania antagonisty receptora interleukiny-1
US8753690B2 (en) 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
AU2009246430B2 (en) 2008-05-13 2015-07-02 Novimmune S.A. Anti-IL-6/IL-6R antibodies and methods of use thereof
US20100074881A1 (en) * 2008-07-11 2010-03-25 Parion Sciences, Inc. Multiple nebulizer systems
EP2470162B1 (en) 2009-08-27 2019-03-27 Biomet Biologics, LLC Implantable device for production of interleukin-1 receptor antagonist
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
CA2838529C (en) 2011-06-07 2020-03-24 Parion Sciences, Inc. Methods of treatment
US20130281405A1 (en) * 2012-04-02 2013-10-24 Lenard M. Lichtenberger Use of pc-nsaids to treat and/or prevent pulmonary inflammation
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US9878011B2 (en) * 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
CA2910766C (en) 2013-04-30 2020-12-15 Otitopic Inc. Dry powder formulations and methods of use
US9833474B2 (en) 2013-11-26 2017-12-05 Biomet Biologies, LLC Methods of mediating macrophage phenotypes
WO2016044775A1 (en) * 2014-09-19 2016-03-24 Aerovu Technologies, Inc. Spacer device with flow rate spirometer cross reference to related application (s)
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CA3076353A1 (en) 2017-09-22 2019-03-28 Otitopic Inc. Dry powder compositions with magnesium stearate
CA3083953A1 (en) * 2017-12-11 2019-06-20 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス,エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法
WO2020021574A1 (en) * 2018-07-27 2020-01-30 Wockhardt Limited Pharmaceutical compositions and methods
AU2020395766A1 (en) * 2019-12-02 2022-06-16 Onspira Therapeutics, Inc. Treatment of lower airways disorders
US20230210768A1 (en) * 2020-05-21 2023-07-06 Altavant Sciences Gmbh An inhaled il-1 blockade treatment for respiratory tract immunopathology
WO2022016068A1 (en) * 2020-07-16 2022-01-20 Tbd Pharma Llc Dexamethasone solution for the treatment of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infections
WO2022051247A1 (en) * 2020-09-01 2022-03-10 Dianomi Therapeutics, Inc. Methods for treating or preventing inflammatory events
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
EP4326231A1 (en) * 2021-04-22 2024-02-28 Onspira Therapeutics, Inc. Compositions of interleukin-1 receptor antagonist
EP4417215A1 (en) * 2023-02-20 2024-08-21 Sorbonne Universite Interleukin-1 for the treatment and prevention of allergies
WO2025193658A1 (en) * 2024-03-12 2025-09-18 Hikma Pharmaceuticals Usa Inc. Azithromycin liquid formulation

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US5851526A (en) 1985-04-19 1998-12-22 Ludwig Institute For Cancer Research Methods of treating colon cancer utilizing tumor-specific antibodies
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
DE3888224T2 (de) 1987-04-24 1994-07-21 Teijin Ltd Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung.
US5306620A (en) 1987-07-08 1994-04-26 The Scripps Research Institute Antibodies that bind to a ligand-induced binding site on integrin and induce integrin activation
US5204445A (en) 1988-10-03 1993-04-20 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5149780A (en) 1988-10-03 1992-09-22 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5360716A (en) 1988-10-24 1994-11-01 Otsuka Pharmaceutical Co., Ltd. Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α
US5223395A (en) 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5498694A (en) 1989-05-25 1996-03-12 La Jolla Cancer Research Foundation Peptides of the cytoplasmic domain of integrin
US5644034A (en) 1989-08-07 1997-07-01 Peptide Technology Ltd. Tumour necrosis factor binding ligands
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
US5959087A (en) 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US5196511A (en) 1989-12-01 1993-03-23 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5262520A (en) 1989-12-01 1993-11-16 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
DE4006269A1 (de) 1990-02-28 1991-08-29 Max Planck Gesellschaft Antikoerper gegen den tumor-nekrosefaktor-rezeptor
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
US5830678A (en) 1990-10-30 1998-11-03 Fred Hutchinson Cancer Research Center Method for identifying a target peptide that modulates the binding of epinectin ligand to integrin receptors
US5994510A (en) 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
EP0571442A4 (en) 1991-01-14 1995-05-03 Univ New York PROTEIN TSG-14 INDUCED BY CYTOKINE, DNA ENCODING THE PROTEIN AND USES THEREOF.
DE69219913T2 (de) 1991-01-15 1997-09-11 Bayer Ag Ergänzung von Oberflächenrezeptoren
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5310874A (en) 1991-05-03 1994-05-10 The Scripps Research Institute Integrin α subunit cytoplasmic domain polypeptides and antibodies
DE69230613T2 (de) 1991-07-02 2000-12-28 Inhale Inc Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform
US5334380A (en) 1991-09-27 1994-08-02 Board Of Regents, The University Of Texas System Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
DE69322860T2 (de) 1992-04-03 1999-07-01 Genentech, Inc., South San Francisco, Calif. Antikörper gegen alpha v beta 3 integrin
US5478725A (en) 1992-06-12 1995-12-26 University Of Pennsylvania αv β3 integrin as a predictor of endometriosis
AU4829593A (en) 1992-09-23 1994-04-12 Fisons Plc Inhalation device
ATE155043T1 (de) 1992-10-08 1997-07-15 Kennedy Inst Of Rheumatology Behandlung von autoimmun- und entzundungskrankheiten
ATE174804T1 (de) 1992-10-19 1999-01-15 Dura Pharma Inc Trockenpulverinhalator
US5705481A (en) 1992-11-06 1998-01-06 Merck Patent Gesellschaft Mit Beschrankter Haftung Cyclopeptides
ATE172933T1 (de) 1993-01-19 1998-11-15 Glaxo Group Ltd Aerosol-spender und verfahren zu seiner herstellung
DE4310643A1 (de) 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
US5579578A (en) 1993-10-27 1996-12-03 Hayes Wheels International, Inc. Method for producing a rim for a vechicle wheel
IT1273790B (it) 1994-02-18 1997-07-10 Guidotti & C Spa Labor Derivati eterociclici diazotati aventi attivita' aii antagonista
US5523209A (en) 1994-03-14 1996-06-04 The Scripps Research Institute Methods for identifying inhibitors of integrin activation
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
DE4415310A1 (de) 1994-04-30 1995-11-02 Merck Patent Gmbh Cyclopeptide
EP0766564A4 (en) 1994-06-24 1998-09-23 Immunex Corp SLOW RELEASE POLYPEPTIDES COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL CONDITIONS
US5579758A (en) 1994-07-13 1996-12-03 Century; Theodore J. Sub-miniature aerosolizer with helical flow path formed by threaded insert
DK0719859T3 (da) 1994-12-20 2003-10-20 Merck Patent Gmbh Anti-alfa V-integrin monoklonalt antistof
US5513630A (en) 1995-03-08 1996-05-07 Century; Theodore J. Powder dispenser
US5780426A (en) 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
US5767071A (en) 1995-06-07 1998-06-16 Ixsys Incorporated Sevenmer cyclic peptide inhibitors of diseases involving αv β3
ZA967182B (en) 1995-08-24 1998-05-25 Magainin Pharma Asthma associated factors as targets for treating atopic allergies including asthma and related disorders.
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
GB9526100D0 (en) 1995-12-20 1996-02-21 Intersurgical Ltd Nebulizer
CA2241880A1 (en) 1996-01-03 1997-07-17 Glaxo Group Limited Inhalation device
US5817457A (en) 1996-02-07 1998-10-06 Ma Bioservices, Inc. Methods and kits for detecting viral reverse transcriptase activity in a sample using an acidic pH or an elevated temperature
ES2270475T3 (es) 1996-11-27 2007-04-01 Bristol-Myers Squibb Pharma Company Nuevos antagonistas de receptores de integrina.
US5863769A (en) * 1997-01-28 1999-01-26 Smithkline Beecham Corporation DNA encoding interleukin-1 receptor antagonist (IL-1raβ)
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US5921447A (en) 1997-02-13 1999-07-13 Glaxo Wellcome Inc. Flow-through metered aerosol dispensing apparatus and method of use thereof
EP1491632A3 (en) 1997-03-12 2006-01-04 Smithkline Beecham Corporation Anti-alphavbeta3 humanized monoclonal antibodies
US6171588B1 (en) 1997-04-11 2001-01-09 G. D. Searle & Company Anti-αvβ3 integrin antibody antagonists
US5968741A (en) 1997-04-11 1999-10-19 Cedars-Sinai Medical Center Methods of diagnosing a medically resistant clinical subtype of ulcerative colitis
US6171787B1 (en) 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease
US6096707A (en) 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6016800A (en) 1997-10-24 2000-01-25 Century; Theodore J. Intrapulmonary aerosolizer
AU1249299A (en) * 1997-11-25 1999-06-15 Brax Genomics Limited Chimeric antisense oligonucleotides against tnf-alpha and their uses
AU1523199A (en) 1997-11-26 1999-06-15 Du Pont Pharmaceuticals Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as alphavbeta3 antagonists
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
JP2002505095A (ja) 1998-03-03 2002-02-19 マガイニン ファーマシューティカルズ インコーポレイテッド 喘息及び関連疾患を含むアトピー性アレルギーを治療するための標的としての喘息関連因子
US6294655B1 (en) * 1998-04-03 2001-09-25 Hyseq, Inc. Anti-interleukin-1 receptor antagonist antibodies and uses thereof
US6541623B1 (en) * 1998-04-03 2003-04-01 Hyseq, Inc. Interleukin—1 receptor antagonist and uses thereof
AU748621B2 (en) 1998-08-13 2002-06-06 Merck & Co., Inc. Integrin receptor antagonists
US6160099A (en) 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US6114517A (en) 1998-12-10 2000-09-05 Isis Pharmaceuticals Inc. Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules
US6982089B2 (en) * 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
IL140054A0 (en) * 1999-04-06 2002-02-10 Univ East Carolina Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy (ies) and surfactant depletion
ATE390482T1 (de) * 1999-05-20 2008-04-15 Nuvelo Inc Interleukin-1 hy2. mittel und verfahren
US6531580B1 (en) 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
US20020068279A1 (en) * 1999-12-06 2002-06-06 Curagen Corporation Novel Proteins and nucleic acids encoding the same
DE60127098T2 (de) 2000-01-31 2007-11-29 Genaera Corp. Inhibitoren der mucin-synthese
WO2002032418A1 (en) 2000-10-16 2002-04-25 Duke University Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis
EP1328260A2 (en) * 2000-10-18 2003-07-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US20020156009A1 (en) * 2000-11-02 2002-10-24 Dennis Ballinger Novel interleukin - 1 Hy2 materials and methods
US20020128179A1 (en) * 2000-12-01 2002-09-12 Tacon William C. Shaped microparticles for pulmonary drug delivery
EP1409536A2 (en) * 2001-02-12 2004-04-21 Curagen Corporation Human proteins and nucleic acids encoding same
IL157706A0 (en) 2001-03-02 2004-03-28 Medimmune Inc METHODS OF PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING INTEGRIN alphav beta3 ANTAGONISTS
WO2002085308A2 (en) * 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
AUPR527801A0 (en) * 2001-05-25 2001-06-21 University Of Sydney, The Animal husbandry iii
EP1416957A4 (en) * 2001-07-25 2006-08-02 Nuvelo Inc TREATMENT OF DISORDERS RELATING TO IMMUNE CELLS AND B CELLS
WO2003047510A2 (en) 2001-11-30 2003-06-12 Centocor, Inc. Anti-tnf antibodies, compositions, methods and uses
AU2003213647A1 (en) 2002-02-27 2003-09-09 Emory University Multimeric binding complexes
JP4133017B2 (ja) 2002-06-20 2008-08-13 株式会社資生堂 毛髪処理用組成物
US7572770B2 (en) 2002-06-27 2009-08-11 University Of Zurich Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes
GB0300427D0 (en) * 2003-01-09 2003-02-05 Univ Strathclyde Pharmaceutical composition
WO2004098596A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and il-1 trap
US20050186175A1 (en) * 2004-02-20 2005-08-25 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on benzilic acid esters and soluble TNF receptor fusion proteins
US7507745B2 (en) * 2004-02-20 2009-03-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins
WO2006059108A2 (en) * 2004-12-02 2006-06-08 Domantis Limited ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
GB0426609D0 (en) 2004-12-03 2005-01-05 Ic Innovations Ltd Analysis
WO2006075776A1 (ja) 2005-01-13 2006-07-20 Anges Mg, Inc. 慢性閉塞性肺疾患(COPD)、嚢胞性線維症(Cystic Fibrosis)または肺高血圧症(pulmonary hypertension)治療剤
EP2163562B1 (en) * 2005-06-21 2013-09-18 XOMA Technology Ltd. IL-1beta binding antibodies and fragments thereof
US7860342B2 (en) * 2005-07-01 2010-12-28 The Invention Science Fund I, Llc Modifying restricted images
TW200745003A (en) * 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
TW200738243A (en) * 2005-11-15 2007-10-16 Glaxo Group Ltd Novel process and formulations
CA2629850A1 (en) * 2005-12-01 2007-06-07 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
DE602006008665D1 (de) * 2005-12-21 2009-10-01 Meda Pharma Gmbh & Co Kg Kombination von r,r-glycopyrrolat, rolipram und budesonid zur behandlung von entzündungskrankheiten
US7504106B2 (en) * 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
CA2657581A1 (en) * 2006-07-11 2008-01-17 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
CA2660519A1 (en) 2006-08-10 2008-02-21 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
CA2772567A1 (en) * 2009-09-06 2011-03-10 Protab Ltd. Humanized antibodies specific for hsp65-derived peptide-6 methods and uses thereof

Similar Documents

Publication Publication Date Title
JP2010500360A5 (enExample)
JP6820743B2 (ja) 炎症性疾患におけるil−18結合タンパク質(il−18bp)
US7582297B2 (en) Methods of treating respiratory conditions
JP2019531273A5 (enExample)
JP2020510662A5 (enExample)
JP2010515742A5 (enExample)
JP2024075713A5 (enExample)
CY1122533T1 (el) Ανακινρα για χρηση στην αντιμετωπιση συνδρομου αποφρακτικης βρογχιολιτιδας
JP2009539841A5 (enExample)
JP2011507891A5 (enExample)
JP2017526713A (ja) 線維症を処置するためのセニクリビロック併用療法
JP2017113019A5 (enExample)
JP2007522229A5 (enExample)
RU2018100129A (ru) Способы лечения подагры
AU2015230986A1 (en) Cenicriviroc for the treatment of fibrosis
JP6469012B2 (ja) インターロイキン−6に対する抗体およびその使用
JP2005506331A5 (enExample)
JP2022188083A5 (enExample)
ES2614735T3 (es) Métodos y composiciones para tratar los trastornos relacionados con fibrosis usando antagonistas de la IL-17
CN113350353A (zh) 呼吸性疾病的治疗
JP2020507587A5 (enExample)
Freches et al. PEGylation prolongs the pulmonary retention of an anti-IL-17A Fab’antibody fragment after pulmonary delivery in three different species
JP2012522788A5 (enExample)
JP2005506345A5 (enExample)
JP6878596B2 (ja) Fxrアゴニストの組合せ